{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:34:08Z","timestamp":1792481648937,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["IIRPIG-2023-0000318"],"award-info":[{"award-number":["IIRPIG-2023-0000318"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110353","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:39:42Z","timestamp":1786491582000},"page":"110353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Recent advances in synthetic strategies of fourth-generation EGFR tyrosine kinase inhibitors under clinical trials for the treatment of resistant non-small cell lung cancer (NSCLC)"],"prefix":"10.1016","volume":"181","author":[{"given":"Vaibhav M.","family":"Kadam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harun M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110353_bb0005","first-page":"1","article-title":"Lung cancers: molecular characterization","author":"Cells","year":"2018","journal-title":"Clonal"},{"key":"10.1016\/j.bioorg.2026.110353_bb0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024, CA","volume":"74","author":"Siegel","year":"2024","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.110353_bb0015","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2026","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bioorg.2026.110353_bb0020","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110353_bb0025","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung Cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110353_bb0030","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110353_bb0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejmech.2017.05.027","article-title":"Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance","volume":"142","author":"Patel","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110353_bb0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110353_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108991","article-title":"Quinazoline-based fourth-generation EGFR tyrosine kinase inhibitors to overcome C797S-mediated resistance in non-small cell lung Cancer (NSCLC)","volume":"165","author":"Patil","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110353_bb0050","series-title":"First- and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-naive EGFR mutation-positive non-small cell lung cancer?","first-page":"1","author":"Takeda","year":"2019"},{"key":"10.1016\/j.bioorg.2026.110353_bb0055","article-title":"EGFR first- and second-generation TKIs \u2014 there is still place for them in EGFR-mutant NSCLC patients","volume":"8","author":"Karachaliou","year":"2019"},{"key":"10.1016\/j.bioorg.2026.110353_bb0060","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005"},{"key":"10.1016\/j.bioorg.2026.110353_bb0065","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1142\/S2737416526500365","article-title":"Fragment-based de novo discovery of fourth-generation EGFR-L858R\/T790M\/C797S-tyrosine kinase inhibitors targeting catalytic Lys745 residue to overcome the osimertinib resistance","volume":"25","author":"Joshi","year":"2026","journal-title":"J. Comput. Biophys. Chem."},{"key":"10.1016\/j.bioorg.2026.110353_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1142\/S2737416526500754","article-title":"Optimizing the cardiotoxicity profile of osimertinib via scaffold hopping: an integrated cheminformatics and molecular modeling approach","author":"Nagpure","year":"2026","journal-title":"J. Comput. Biophys. Chem."},{"key":"10.1016\/j.bioorg.2026.110353_bb0075","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/LCTT.S119644","article-title":"Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy","volume":"8","author":"Santarpia","year":"2017","journal-title":"Lung Cancer Targets Ther."},{"issue":"26","key":"10.1016\/j.bioorg.2026.110353_bb0080","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non\u2013small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110353_bb0090","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1021\/jm500973a","article-title":"Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor","volume":"57","author":"Finlay","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110353_bb0095","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1021\/acsmedchemlett.0c00472","article-title":"Complex crystal structures of EGFR with third-generation kinase inhibitors and simultaneously bound allosteric ligands","volume":"11","author":"Niggenaber","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110353_bb0100","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1021\/acsmedchemlett.2c00514","article-title":"Addressing the osimertinib resistance mutation EGFR-L858R\/C797S with reversible aminopyrimidines","volume":"14","author":"Grabe","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110353_bb0105","doi-asserted-by":"crossref","first-page":"10789","DOI":"10.1039\/C9SC03445E","article-title":"Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M\/C797S","volume":"10","author":"Lategahn","year":"2019","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bioorg.2026.110353_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117140","article-title":"Catalytic Lysine745 targeting strategy in fourth-generation EGFR tyrosine kinase inhibitors to address C797S mutation resistance","volume":"283","author":"Patil","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110353_bb0115","first-page":"6540","article-title":"Targeting C797S mutations and beyond in non-small cell lung cancer \u2014 a mini-review","volume":"13","author":"Dempke","year":"2024"},{"key":"10.1016\/j.bioorg.2026.110353_bb0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110353_bb0125","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1039\/D4MD00384E","article-title":"Medicinal chemistry","volume":"15","author":"Das","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110353_bb0130","series-title":"Strategies beyond 3rd EGFR-TKI acquired resistance: opportunities and challenges","first-page":"1","author":"Zhou","year":"2025"},{"key":"10.1016\/j.bioorg.2026.110353_bb0135","series-title":"Intrinsic Resistance to EGFR-Tyrosine Kinase","first-page":"1","author":"Santoni-rugiu","year":"2019"},{"key":"10.1016\/j.bioorg.2026.110353_bb0140","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1158\/1078-0432.CCR-22-3901","article-title":"BBT-176, a novel fourth-generation tyrosine kinase inhibitor for osimertinib-resistant EGFR mutations in non\u2013small cell lung cancer","volume":"29","author":"Lim","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110353_bb0145","doi-asserted-by":"crossref","first-page":"9662","DOI":"10.1021\/acs.jmedchem.2c00704","article-title":"Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant Inhibitor for treatment-resistant non-small-cell lung Cancer","volume":"65","author":"Eno","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110353_bb0150","series-title":"Present and Future","first-page":"217","volume":"12","author":"Chevallier","year":"2021"},{"key":"10.1016\/j.bioorg.2026.110353_bb0155","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/13543784.2022.2075341","article-title":"A phase 1b\/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer","volume":"31","author":"Cho","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bioorg.2026.110353_bb0160","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/13543776.2025.2536006","article-title":"Overcoming triple mutant EGFR-tyrosine kinase barriers in the therapeutics of non-small cell lung cancer: a patent review on fourth-generation inhibitors (2017\u20132024)","volume":"35","author":"Nagpure","year":"2025","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2026.110353_bb0165","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non\u2013small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2026.110353_bb0170","unstructured":"https:\/\/clinicaltrials.gov\/search?term=TQB3804&viewType=Card [Access date 12th August 2026]."},{"key":"10.1016\/j.bioorg.2026.110353_bb0175","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1158\/1538-7445.AM2019-1320","article-title":"Abstract 1320: preclinical evaluation of TQB3804, a potent EGFR C797S inhibitor","volume":"79","author":"Liu","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110353_bb0180","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05393466?term=BPI-361175 [Access date 12th August 2026]."},{"key":"10.1016\/j.bioorg.2026.110353_bb0185","series-title":"EGFR Inhibitor, Composition, and Preparation Method Therefor","author":"Betta Pharmaceuticals Co Ltd","year":"2022"},{"key":"10.1016\/j.bioorg.2026.110353_bb0190","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04862780?term=blu%20945 [Access date 12th August 2026]."},{"key":"10.1016\/j.bioorg.2026.110353_bb0195","author":"Blueprint Medicines Corporation","year":"2021"},{"key":"10.1016\/j.bioorg.2026.110353_bb0200","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04820023?term=BBT-176 [Access date 12th August 2026]."},{"key":"10.1016\/j.bioorg.2026.110353_bb0205","unstructured":"https:\/\/www.prnewswire.com\/news-releases\/bridge-biotherapeutics-announces-initiation-of-phase-12-clinical-trial-of-bbt-207-in-egfr-mutant-nsclc-301971198.html [Access date 12th August 2026]."},{"key":"10.1016\/j.bioorg.2026.110353_bb0210","series-title":"A Phase 1\/2, Open-Label Study of BBT-176, a Triple Mutation Targeting EGFR TKI, in Patients with NSCLC Who Progressed after Prior EGFR TKI Therapy, ESMO 2021","author":"Bridge Biotherapeutics Inc.","year":"2026"},{"key":"10.1016\/j.bioorg.2026.110353_bb0215","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05256290?term=BDTX-1535 [Access date 12th August 2026]."},{"key":"10.1016\/j.bioorg.2026.110353_bb0220","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05555212?term=QLH11811 [Access date 12th August 2026]."},{"key":"10.1016\/j.bioorg.2026.110353_bb0225","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1158\/1538-7445.AM2022-5457","article-title":"Abstract 5457: QLH11811, a selective 4th-generation EGFR inhibitor for osimertinib-resistant EGFR -mutant NSCLC","volume":"82","author":"Zheng","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110353_bb0230","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05435248?term=HS-10375 [Access date 12th August 2026]."},{"key":"10.1016\/j.bioorg.2026.110353_bb0235","unstructured":"L. Jiangsu Hansoh Pharmaceutical Group Co., Crystal form of aryl phosphorus oxide derivative free base, preparation method therefor, and application thereof, WO2022127807A1, 2022."},{"key":"10.1016\/j.bioorg.2026.110353_bb0240","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05519293?term=H002 [Access date 12th August 2026]."},{"key":"10.1016\/j.bioorg.2026.110353_bb0245","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1158\/1538-7445.AM2022-5461","article-title":"Abstract 5461: H002: a wide spectrum, highly selective fourth-generation EGFR inhibitor overcoming resistance harboring C797S mutation in NSCLC","volume":"82","author":"Huang","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110353_bb0250","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05153408?term=BLU-701 [Access date 12th August 2026]."},{"key":"10.1016\/j.bioorg.2026.110353_bb0255","series-title":"BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC, AACR 2021","author":"Blueprint Medicines Corporation","year":"2021"},{"key":"10.1016\/j.bioorg.2026.110353_bb0260","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05394831?term=JIN-A02 [Access date 12th August 2026]."},{"key":"10.1016\/j.bioorg.2026.110353_bb0265","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jtho.2022.07.117","article-title":"MA07.08 JIN-A02, a highly effective 4th generation EGFR-TKI, targeting EGFR C797S triple mutation in NSCLC","volume":"17","author":"Yun","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2026.110353_bb0270","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05920135?term=BBT-207 [Access date 12th August 2026]."},{"key":"10.1016\/j.bioorg.2026.110353_bb0275","series-title":"BBT-207, A 4th Generation EGFR TKI With Broad-Spectrum Activity to Both Treatment-Emergent and Drug-Na\u00efve Mutants for the Treatment of NSCLC, AACR 2022","author":"I. Bridge Biotherapeutics","year":"2022"},{"key":"10.1016\/j.bioorg.2026.110353_bb0280","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT06590194?term=PH009-1 [Access date 12th August 2026]."},{"key":"10.1016\/j.bioorg.2026.110353_bb0285","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1158\/1538-7445.AM2023-4005","article-title":"Abstract 4005: PH009-1, a highly potent and selective fourth-generation EGFR-TKI overcoming EGFR common mutations and T790M\/C797S-mediated resistance in NSCLC","volume":"83","author":"Gao","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110353_bb0290","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05765734?term=TAS3351 [Access date 12th August 2026]."},{"key":"10.1016\/j.bioorg.2026.110353_bb0295","series-title":"The 4 th Medium-Term Management Plan","author":"Otsuka","year":"2024"},{"key":"10.1016\/j.bioorg.2026.110353_bb0300","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT06461156?term=HS-10504 [Access date 12th August 2026]."},{"key":"10.1016\/j.bioorg.2026.110353_bb0305","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT06186076?term=TRX-221 [Access date 12th August 2026]."},{"key":"10.1016\/j.bioorg.2026.110353_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118146","article-title":"A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer","volume":"123","author":"Gawli","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110353_bb0315","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04128085 TQB3804 [Access date 12th August 2026]."},{"key":"10.1016\/j.bioorg.2026.110353_bb0320","series-title":"Salt of egfr inhibitor, crystal form, and preparation method therefor","author":"Chia Tai Tianqing Pharmaceutical Group Co Ltd","year":"2022"},{"key":"10.1016\/j.bioorg.2026.110353_bb0325","series-title":"Pharmaceutical compositions of an epidermal growth factor receptor inhibitor","author":"Blueprint Medicines Corporation","year":"2022"},{"key":"10.1016\/j.bioorg.2026.110353_bb0330","series-title":"N2,n4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer","author":"Korea Research Institute of Chemical Technology","year":"2020"},{"key":"10.1016\/j.bioorg.2026.110353_bb0335","series-title":"Alkynyl quinazoline compounds","author":"Black Diamond Therapeutics","year":"2021"},{"key":"10.1016\/j.bioorg.2026.110353_bb0340","series-title":"Novel Aminopyrimidine EGFR (Epidermal Growth Factor Receptor) Inhibitor","author":"Qilu Pharmaceutical Co Ltd","year":"2021"},{"key":"10.1016\/j.bioorg.2026.110353_bb0345","series-title":"Egfr Inhibitor and Preparation Method and Use Thereof","author":"Hongyun Biotech Co Ltd","year":"2023"},{"key":"10.1016\/j.bioorg.2026.110353_bb0350","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05662670?term=WJ13404 [Access date 12th August 2026]."},{"key":"10.1016\/j.bioorg.2026.110353_bb0355","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1158\/1538-7445.AM2022-3259","article-title":"Abstract 3259: TAS3351 is a 4th-generation EGFR-TKI overcoming T790M and C797S-mediated resistance in NSCLC with EGFR common mutations","volume":"82","author":"Kasuga","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110353_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1385","article-title":"2357P TRX-221, a 4th generation, mutant-selective, and CNS-active EGFR inhibitor with robust antitumor activity in osimertinib-resistant tumor models harboring C797S mutation","volume":"34","author":"Lim","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.110353_bb0365","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1021\/acschembio.4c00028","article-title":"Chemical scaffolds for the clinical development of mutant-selective and reversible fourth-generation EGFR-TKIs in NSCLC","volume":"19","author":"Laudadio","year":"2024","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110353_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111888","article-title":"Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R\/T790M\/C797S mutant EGFR tyrosine kinase inhibitors","volume":"186","author":"Lei","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110353_bb0375","doi-asserted-by":"crossref","first-page":"18463","DOI":"10.1021\/acs.jmedchem.5c01313","article-title":"Direct Ser797 interacted Pteridine-7(8 H)-one derivatives as highly selective and orally available EGFR L858R\/T790M\/C797S inhibitors","volume":"68","author":"Jiang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110353_bb0380","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1021\/acs.jcim.2c01586","article-title":"Mechanistic modeling of Lys745 sulfonylation in EGFR C797S reveals chemical determinants for inhibitor activity and discriminates reversible from irreversible agents","volume":"63","author":"Arafet","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2026.110353_bb0390","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110353_bb0395","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110353_bb0400","doi-asserted-by":"crossref","first-page":"20943","DOI":"10.1021\/acsami.5c01103","article-title":"Targeted degradation of EGFR mutations via self-delivery nano-PROTACs for boosting tumor synergistic immunotherapy","volume":"17","author":"Wang","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bioorg.2026.110353_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112781","article-title":"Discovery of potent small molecule PROTACs targeting mutant EGFR","volume":"208","author":"Zhao","year":"2020","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:02:35Z","timestamp":1791406955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826008898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":79,"alternative-id":["S0045206826008898"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110353","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in synthetic strategies of fourth-generation EGFR tyrosine kinase inhibitors under clinical trials for the treatment of resistant non-small cell lung cancer (NSCLC)","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110353"}}